Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest

International Journal of Cancer

Volumn 113, Issue 4, 2005, Pages 541-548

  Yazawa, Kentaro ^a   Tsuno, Nelson H ^a   Kitayama, Joji ^a   Kawai, Kazushige ^a   Okaji, Yurai ^a   Asakage, Masahiro ^a   Sunami, Eiji ^a   Kaisaki, Shoichi ^a   Hori, Nobukazu ^a   Watanabe, Toshiaki ^a   Takahashi, Koki ^a   Nagawa, Hirokazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiogenesis; Cell cycle; Cell proliferation; Endothelial cells; Selective COX 2 inhibitor

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; TILMACOXIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOSIS INHIBITION; PRIORITY JOURNAL; UMBILICAL VEIN;

APOPTOSIS; BENZENESULFONATES; CELL ADHESION; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; G1 PHASE; HUMANS; ISOENZYMES; MATRIX METALLOPROTEINASE 2; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; OXAZOLES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; UMBILICAL VEINS;

EID: 19944404199     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20621     Document Type: Article

References (44)

1. Marnett LJ. Aspirin and related non-steroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prev Med 1995;24:103-6.
2. Dubois RN. Review article: cyclooxygenase - a target for colon cancer prevention. Aliment Pharmacol Ther 2000;14(Suppl 1):64-7.
3. Seibert K, Masferrer J. Zhang Y, Leahy K, Hauser S, Gierse J, Koboldt C, Anderson G, Bremer M, Gregory S. Expression and selective inhibition of constitutive and inducible forms of cyclooxygenase. Adv Prostaglandin Thromboxane Leukot Res 1995;23:125-7.
4. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 1998;95:13313-8.
5. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
6. Tenenbaum J. The epidemiology of nonsteroidal anti-inflammatory drugs. Can J Gastroenterol 1999;13:119-22.
7. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
8. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002;97:1037-41.
9. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, Saito S, Tsuruo T, Shibata Y, Nagawa H. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-8.
10. Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada T, Kitayama J, Sunami E, Nita ME, Ishihara S, Yano H, Tsuruo T, Shibata Y, et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer 1999;81:1274-9.
11. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996;56:4566-9.
12. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-9.
13. Wei M, Morimura K, Wanibuchi H, Shen J, Doi K, Mitsuhashi M, Moku M, Salim EI, Fukushima S. Chemopreventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Cancer Lett 2003;202:11-6.
14. Nagatsuka I, Yamada N, Shimizu S, Ohira M, Nishino H, Seki S, Hirakawa K. Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer. Int J Cancer 2002;100:515-9.
15. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625-31.
16. North GL. Celecoxib as adjunctive therapy for treatment of colorectal cancer. Ann Pharmacother 2001;35:1638-43.
17. Kismet K, Akay MT, Abbasoglu O, Ercan A. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev 2004;28:127-42.
18. Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 1999;8:1623-38.
19. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
20. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
21. Yoshida M, Szente BE, Kiely JM, Rosenzweig A, Gimbrone MA Jr. Phosphorylation of the cytoplasmic domain of E-selectin is regulated during leukocyte-endothelial adhesion. J Immunol 1998;161:933-41.
22. Wakitani K, Nanayama T, Masaki M, Matsushita M. Profile of JTE-522 as a human cyclooxygenase-2 inhibitor. Jpn J Pharmacol 1998;78:365-71.
23. Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, Mizushima Y. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol 1998;347:87-94.
24. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
25. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
26. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
27. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima O, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29:688-96.
28. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80.
29. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ 3rd. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-90.
30. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 2001;29:23-8.
31. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
32. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
33. Okami J, Nakamori S, Hiraoka N, Tsujie M, Hayashi N, Yamamoto H, Fujiwara Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M. Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor. Clin Exp Metastasis 2003;20:577-84.
34. Church RD, Fleshman JW, McLeod HL. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg 2003;90:1055-67.
35. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
36. Wang D, DuBois RN. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A 2004;101:415-6.
37. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, Etodolac. Int J Cancer 2001;91:894-9.
38. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-8.
39. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000;14:2393-409.
40. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci (Lond) 2002;102:417-24.
41. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer 1996;32A:2423-9.
42. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997;277:48-50.
43. Woods JM, Mogollon A, Amin MA, Martinez RJ, Koch AE. The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 2003;74:282-90.
44. Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, Morrow JD, DuBois RN. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 1998;19:2195-9.